/ /

  • linkedin
  • Increase Font
  • Sharebar

    Rescue alfibercept treatment proves successful for patients with BRVO

    Improved, sustained VA outcomes for branch retinal vein occlusion patients compared with laser


    A look at the results at 24 weeks in the laser group showed that the laser and intravitreal aflibercept-treated patients received a slightly higher mean number of laser treatments compared with the patients who received only laser treatment.

    In the laser group at 24 weeks, more patients treated with laser only gained 15 or more letters of VA compared with those who were subsequently treated with laser and intravitreal aflibercept.  However, with intravitreal aflibercept rescue, at 52 weeks, the number of patients achieving a 15 or greater gain in letters was closer to that in the laser only group.

    A decrease in the CRT was seen along with the increase in the VA. The CRT decreased substantially more in the laser and intravitreal aflibercept group at 52 weeks compared with the laser only group.

    “Overall intravitreal aflibercept was superior to laser treatment through week 24 for VA and anatomic outcomes,” Dr. Lim said.


    Jennifer I. Lim, MD

    E: [email protected]

    Dr. Lim is on the advisory boards and speaker’s bureaus of Genentech Inc. and Regeneron Pharmaceuticals.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results